单克隆抗体治疗多发性骨髓瘤的研究进展

国际输血及血液学杂志 Pub Date : 2019-01-20 DOI:10.3760/CMA.J.ISSN.1673-419X.2019.01.009

Y. Liao, Mengyao Wang

{"title":"单克隆抗体治疗多发性骨髓瘤的研究进展","authors":"Y. Liao, Mengyao Wang","doi":"10.3760/CMA.J.ISSN.1673-419X.2019.01.009","DOIUrl":null,"url":null,"abstract":"The treatment of multiple myeloma (MM) has developed rapidly in the past decade, due to the notable effect of protease inhibitors (PI) and immunomodulatory drugs (IMID). However, MM remains incurable in the vast majority of cases. Recently, a large number of studies have found that monoclonal antibodies, such as a targeted approach can significantly increase remission rate or survival for patients with MM, including relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). This review focuses on the recent developments in monoclonal antibody-based therapy for MM in terms of targets, efficacy and safety. \n \n \nKey words: \nMultiple myeloma; Antibodies, monoclonal; Antigens; Molecular targeted therapy; Treatment outcome; Clinical protocols; Drug-related side effects and adverse reactions","PeriodicalId":13774,"journal":{"name":"国际输血及血液学杂志","volume":"42 1","pages":"53-60"},"PeriodicalIF":0.0000,"publicationDate":"2019-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Research progress of monoclonal antibodies in treatment of multiple myeloma\",\"authors\":\"Y. Liao, Mengyao Wang\",\"doi\":\"10.3760/CMA.J.ISSN.1673-419X.2019.01.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The treatment of multiple myeloma (MM) has developed rapidly in the past decade, due to the notable effect of protease inhibitors (PI) and immunomodulatory drugs (IMID). However, MM remains incurable in the vast majority of cases. Recently, a large number of studies have found that monoclonal antibodies, such as a targeted approach can significantly increase remission rate or survival for patients with MM, including relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). This review focuses on the recent developments in monoclonal antibody-based therapy for MM in terms of targets, efficacy and safety. \\n \\n \\nKey words: \\nMultiple myeloma; Antibodies, monoclonal; Antigens; Molecular targeted therapy; Treatment outcome; Clinical protocols; Drug-related side effects and adverse reactions\",\"PeriodicalId\":13774,\"journal\":{\"name\":\"国际输血及血液学杂志\",\"volume\":\"42 1\",\"pages\":\"53-60\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"国际输血及血液学杂志\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.01.009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际输血及血液学杂志","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-419X.2019.01.009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

由于蛋白酶抑制剂（PI）和免疫调节药物（IMID）的显著作用，多发性骨髓瘤（MM）的治疗在过去十年中发展迅速。然而，MM在绝大多数情况下仍然无法治愈。最近，大量研究发现，单克隆抗体，如靶向方法，可以显著提高MM患者的缓解率或生存率，包括复发/难治性多发性骨髓瘤（RRMM）和新诊断的多发性骨瘤（NDMM）。本文就单克隆抗体治疗MM的靶点、疗效和安全性等方面的最新进展进行综述。关键词：多发性骨髓瘤；单克隆抗体；抗原；分子靶向治疗；治疗结果；临床方案；药物相关副作用和不良反应

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Research progress of monoclonal antibodies in treatment of multiple myeloma

The treatment of multiple myeloma (MM) has developed rapidly in the past decade, due to the notable effect of protease inhibitors (PI) and immunomodulatory drugs (IMID). However, MM remains incurable in the vast majority of cases. Recently, a large number of studies have found that monoclonal antibodies, such as a targeted approach can significantly increase remission rate or survival for patients with MM, including relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). This review focuses on the recent developments in monoclonal antibody-based therapy for MM in terms of targets, efficacy and safety. Key words: Multiple myeloma; Antibodies, monoclonal; Antigens; Molecular targeted therapy; Treatment outcome; Clinical protocols; Drug-related side effects and adverse reactions

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

国际输血及血液学杂志

自引率

0.00%

发文量

10610

期刊介绍： The International Journal of Transfusion and Hematology was founded in September 1978. It is a comprehensive academic journal in the field of transfusion and hematology, supervised by the National Health Commission and co-sponsored by the Chinese Medical Association, West China Second Hospital of Sichuan University, and the Institute of Transfusion Medicine of the Chinese Academy of Medical Sciences. The journal is a comprehensive academic journal that combines the basic and clinical aspects of transfusion and hematology and is publicly distributed at home and abroad. The International Journal of Transfusion and Hematology mainly reports on the basic and clinical scientific research results and progress in the field of transfusion and hematology, new experiences, new methods, and new technologies in clinical diagnosis and treatment, introduces domestic and foreign research trends, conducts academic exchanges, and promotes the development of basic and clinical research in the field of transfusion and hematology.